strekin hearing loss drug

Swiss Biotech, Strekin, Secures Funding for Second Clinical Trial of Hearing Loss Drug

BASEL, SWITZERLAND — Strekin AG announced this week that it had successfully closed a Seed C financing round totaling CHF10 million (approximately $10.3 USD) from private investors. The latest financing round allows the company to conduct a second clinical trial of its leading drug candidate, STR001, as a potential new treatment for sudden sensorineural hearing…

Read More